# The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.

> **NCT07212062** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Neurology Office of South Florida** · enrollment: 60 (estimated)

## Conditions studied

- Alzheimers Disease

## Interventions

- **DRUG:** X/T + X-EC
- **DRUG:** Placebo
- **DRUG:** Lecanemab 10 mg/kg

## Key facts

- **NCT ID:** NCT07212062
- **Lead sponsor:** Neurology Office of South Florida
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07212062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07212062, "The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07212062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*